Prevalence of Pancreas Adenocarcinomas
Conditions
Keywords
pancreas, adenocarcinoma
Brief summary
Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is increasing both in France and in Europe, whereas all the other cancers are decreasing in Europe. Moreover, its seriousness is still high, with a mortality rate higher than the average incidence. The aim of PAPAFA study is to assess the prevalence of the pancreatic anomalies which can be revealed thanks to imaging, for patients having a 1st degree pancreatic adenocarcinoma familial history. This could allow detection of lesions which are less than 10 mm long, and improve the dark prognostic of this pathology.
Interventions
PROCEDUREPancreatic MRI
Pancreatic MRI in the 6 months following the first consultation
Sponsors
Centre Hospitalier Saint Joseph Saint Luc de Lyon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* patients with a 1st degree familial history of pancreas adenocarcinoma * patients older than 40 * patients whose life expectancy is \> 3 months * inform and consent form signed * patient insured under the French social security system
Exclusion criteria
* contraindication to the MRI (pace-maker, implanted metallic material, medical history of allergy to the contrast agent, end-stage renal failure, pregnancy, claustrophobia) * contraindication to anesthesia to do the echo endoscopy * 1st degree family history of 2 pancreas adenocarinomas * medical history of allergy to benzylic alcool * contraindication to dimeglumine gadobenate * pregnant or breastfeeding woman, according to the questioning * subjets who don't have the legal capacity to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients for whom the MRI and/or the echo endoscopy has shown a parenchymatous or ductal pancreatic anomaly | six months after the last inclusion | For every patients who will have a pancreatic MRI detecting an anomaly, the echo endoscopy will be done. A cytology of the lesion from the echo endoscopy will be done for the solid lesions and for the indetermined cystic lesions (that is to say, the lesions which don't meet the literature set criteria for serous kyst or intraductal papillary and mucinous tumor of the pancreas) ; which is usually done in health care. |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients for whom the echo endoscopy has brought to light a parenchymatous and/or ductal pancreatic anomaly | six months after the last inclusion |
| Height of the lesions | six months after the last inclusion |
| Correlation between the data from the MRI and those from the echo endoscopy | six months after the last inclusion |
| Number of patients for whom the MRI has brought to light a parenchymatous and/or ductal pancreatic anomaly | six months after the last inclusion |
| Number of lesions | six months after the last inclusion |
| Aspect of the lesion (solid and/or liquid) | six months after the last inclusion |
| Localisation of the lesions | six months after the last inclusion |
Countries
France
Outcome results
None listed